In 2023 the first potent and selective HSD17B13 inhibitor, BI-3231, was reported.[ 8] Structural Genomics Consortium .[ 9]
^ a b c GRCh38: Ensembl release 89: ENSG00000170509 – Ensembl , May 2017^ a b c GRCm38: Ensembl release 89: ENSMUSG00000034528 – Ensembl , May 2017^ "Human PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .^ "Mouse PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .^ Zhu YS, Imperato-McGinley JL (9 November 2016). "4.02: Disorders of Sexual Development in Males: Molecular Genetics, Epigenetics, Gender Identity, and Cognition" . In Lightman S (ed.). Hormones, Brain and Behavior . Vol. 4: Clinical Important Effects of Hormones on Brain and Behavior. Elsevier Science. p. 69. ISBN 978-0-12-803608-2 ^ Zanders ED (9 November 2015). "Enzymes, Part 2" . Human Drug Targets: A Compendium for Pharmaceutical Discovery . John Wiley & Sons. pp. 257–. ISBN 978-1-118-84985-9 ^ Su W, Wang Y, Jia X, Wu W, Li L, Tian X, et al. (August 2014). "Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease" . Proceedings of the National Academy of Sciences of the United States of America . 111 (31): 11437–11442. Bibcode :2014PNAS..11111437S . doi :10.1073/pnas.1410741111 PMC 4128098 PMID 25028495 . ^ Thamm S, Willwacher MK, Aspnes GE, Bretschneider T, Brown NF, Buschbom-Helmke S, et al. (February 2023). "Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science" . Journal of Medicinal Chemistry . 66 (4): 2832–2850. doi :10.1021/acs.jmedchem.2c01884 . PMC 9969402 PMID 36727857 . ^ "Donated Chemical Probes" . thesgc.org . Retrieved July 31, 2023 .
